Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice

Aruni Jha; Melanie Doyle-Eisele; David Revelli; Trevor Carnelley; Douglas Barker; Shantha Kodihalli

doi:10.3390/v15010123

Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice

Viruses. 2022 Dec 30;15(1):123. doi: 10.3390/v15010123.

Authors

Aruni Jha¹, Melanie Doyle-Eisele², David Revelli², Trevor Carnelley¹, Douglas Barker¹, Shantha Kodihalli¹

Affiliations

¹ Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
² Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA.

Abstract

Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infected transgenic mice compared to controls. COVID-HIGIV also has similar pharmacokinetic profiles in healthy and SARS-CoV-2 infected mice over time after intravenous administration, with identical or comparable Tmax, Cmax, AUC_0-∞ and Cl. AUC_0-last increased and mean residence time, T_1/2, and Vd reduced in infected animals compared to healthy animals. These data suggest that COVID-HIGIV may be an effective treatment for SARS-CoV-2 infection when given early after exposure.

Keywords: COVID-19; mouse model; pharmacodynamics; pharmacokinetics.

Publication types

Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Animals
Antibodies
COVID-19*
Humans
Mice
Pandemics / prevention & control
RNA, Viral
SARS-CoV-2

Substances

RNA, Viral
Antibodies